Modulators of .beta.-amyloid peptide aggregation

US5854215A · kind A · utility

Assignee

• Praecis Pharmaceuticals, Inc. · US

Inventors

• Mark A. Findeis · Belmont, US
• Howard Benjamin · Lexington, US
• Marc B. Garnick · Brookline, US
• Malcolm L. Gefter · Lincoln, US
• Arvind Hundal · Watertown, US
• Laura Kasman · Athens, US
• Gary Musso · Hopkinton, US
• Ethan R. Signer · Cambridge, US
• James Wakefield · Brookline, US
• Michael John Reed · London, GB

Key dates

• Filing date: Jun 7, 1995
• Grant date: Dec 29, 1998
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds that act to modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP) are disclosed. The .beta. amyloid modulators of the invention can promote .beta.-AP aggregation or, more preferably, can inhibit natural .beta.-AP aggregation. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and methods of altering natural .beta.-AP aggregation using the compounds of the invention, are also disclosed.